Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, 510100, China. Address: 106 Zhongshan Er Road, Guangzhou, 510080, PR China.
Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, 510100, China. Address: 106 Zhongshan Er Road, Guangzhou, 510080, PR China.
Biomed Pharmacother. 2020 Dec;132:110813. doi: 10.1016/j.biopha.2020.110813. Epub 2020 Oct 14.
Cardiovascular disease (CVD) is one of the leading causes of death worldwide. Currently, many methods have been proposed by researchers for the prevention and treatment of CVD; among them, stem cell-based therapies are the most promising. As the cells of origin for various mature cells, stem cells have the ability to self-renew and differentiate. Stem cells have a powerful ability to regenerate biologically, self-repair, and enhance damaged functional tissues or organs. Allogeneic stem cells and somatic stem cells are two types of cells that can be used for cardiac repair. Theoretically, dilated cardiomyopathy and acute myocardial infarction can be treated with such cells. In addition, stem cell transplantation procedures, including intravenous, epicardial, cardiac, and endocardial injections, have been reported to provide significant benefits in clinical practice; however, there are still a number of issues that need further study and consideration, such as the form and quantity of transplanted cells and post-transplantation health. The goal of this analysis was to summarize the recent advances in stem cell-based therapies and their efficacy in cardiovascular regenerative medicine.
心血管疾病(CVD)是全球范围内主要的死亡原因之一。目前,研究人员已经提出了许多用于预防和治疗 CVD 的方法,其中,基于干细胞的疗法最有前途。作为各种成熟细胞的起源细胞,干细胞具有自我更新和分化的能力。干细胞具有强大的生物学再生、自我修复和增强受损功能组织或器官的能力。同种异体干细胞和体干细胞是可用于心脏修复的两种细胞类型。理论上,可以用这些细胞治疗扩张型心肌病和急性心肌梗死。此外,已经报道了包括静脉内、心外膜、心脏和心内膜注射在内的干细胞移植程序在临床实践中提供了显著的益处;然而,仍有许多问题需要进一步研究和考虑,例如移植细胞的形式和数量以及移植后的健康状况。本分析的目的是总结基于干细胞的疗法的最新进展及其在心血管再生医学中的疗效。